MedTrace Logo

Comparison of Visceral Adipokines Visfatin, Vaspin and Omentin Levels in Gestational Diabetes Mellitus Pregnant Women

NCT05463237 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 174

Last updated 2023-08-28

No results posted yet for this study

Summary

The prevalence of maternal obesity is increasing rapidly worldwide and constitutes an important obstetric problem that increases mortality and morbidity in both mothers and infants. Obese women are prone to pregnancy complications such as gestational diabetes mellitus (GDM), and children of obese mothers are more likely to develop cardiovascular and metabolic disease later in life. The risk of developing GDM in obese pregnants is 1.3-3.8 times higher than in pregnant women with a normal body mass index, and approximately 70% of women with GDM remain at risk of developing type 2 diabetes until 28 years postpartum. Gestational diabetes mellitus (GDM) affects approximately 6% of pregnant women and its prevalence is increasing in parallel with the obesity epidemic. GDM is associated with an increased risk of adverse pregnancy outcomes, including macrosomia, preterm delivery, neonatal hypoglycemia, neonatal jaundice, and congenital anomalies. It is also associated with a higher incidence of type 2 diabetes mellitus after birth. It is known that visceral adipose tissue increases in obese women. It is thought that there is a relationship between visceral adipose tissue increase and diabetes. In this study, the levels of new adipocytokines such as Visfatin, Vaspin and Omentin secreted from visceral adipose tissue in patients diagnosed with GDM will be measured.

Conditions

  • Gestational Diabetes
  • Obesity
  • Visceral Obesity

Interventions

DIAGNOSTIC_TEST

oral glucose tolerance test

oral glucose tolerance test (OGTT) used for the diagnosis of gestational diabetes mellitus between 24-28 weeks of gestation

DIAGNOSTIC_TEST

Blood sample

Measurement of blood Visfatin, Vaspin and Omentin levels in pregnant women with diabetes

Sponsors & Collaborators

  • Siirt University

    lead OTHER

Principal Investigators

  • Şerif Aksin, Assoc.Prof · Siirt University Medical Faculty Obstetrics and Gynecology Departmant

  • Şerif Aksin · Siirt Üniversity Medical Faculty Obstetrics and Gynecology Department

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-31
Primary Completion
2023-08-25
Completion
2023-08-25

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05463237 on ClinicalTrials.gov